Femasys Inc.
Tracked across 2 events · 12 articles · First seen Aug 07, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Femasys is the issuer of the private placement, raising $30 million with potential additional proceeds. The financing strengthens its balance sheet and supports its business plan, but the stock price declined due to dilution.
Aug 07, 2026 · 6 articles
Regulatory
Impact: Femasys is the developer of FemBloc and the recipient of the FDA's approval of the modular PMA pathway. This approval is a major step toward U.S. commercialization, positively impacting the company's prospects and stock price.
Aug 19, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Femasys Inc. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard